| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ... Science 359 (6378), 920-926, 2018 | 1692 | 2018 |
| Guidelines for the welfare and use of animals in cancer research P Workman, EO Aboagye, F Balkwill, A Balmain, G Bruder, DJ Chaplin, ... British journal of cancer 102 (11), 1555-1577, 2010 | 1513 | 2010 |
| Combinatorial drug therapy for cancer in the post-genomic era B Al-Lazikani, U Banerji, P Workman Nature biotechnology 30 (7), 679-692, 2012 | 1134 | 2012 |
| Hsp90 molecular chaperone inhibitors: are we there yet? L Neckers, P Workman Clinical cancer research 18 (1), 64-76, 2012 | 1111 | 2012 |
| Imaging biomarker roadmap for cancer studies JPB O'connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ... Nature reviews Clinical oncology 14 (3), 169-186, 2017 | 1110 | 2017 |
| The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective … AJ Folkes, K Ahmadi, WK Alderton, S Alix, SJ Baker, G Box, ... Journal of medicinal chemistry 51 (18), 5522-5532, 2008 | 869 | 2008 |
| The promise and peril of chemical probes CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ... Nature chemical biology 11 (8), 536-541, 2015 | 863 | 2015 |
| Animals in experimental neoplasia P Workman Br J Cancer 77 (1), 1-10, 1998 | 786* | 1998 |
| Challenges to curing primary brain tumours K Aldape, KM Brindle, L Chesler, R Chopra, A Gajjar, MR Gilbert, ... Nature reviews Clinical oncology 16 (8), 509-520, 2019 | 774 | 2019 |
| HSP90 as a new therapeutic target for cancer therapy: the story unfolds A Maloney, P Workman Expert opinion on biological therapy 2 (1), 3-24, 2002 | 732 | 2002 |
| Discovery of small molecule cancer drugs: successes, challenges and opportunities S Hoelder, PA Clarke, P Workman Molecular oncology 6 (2), 155-176, 2012 | 718 | 2012 |
| Targeting the PI3K–AKT–mTOR pathway: progress, pitfalls, and promises TA Yap, MD Garrett, MI Walton, F Raynaud, JS de Bono, P Workman Current opinion in pharmacology 8 (4), 393-412, 2008 | 678 | 2008 |
| Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress P Workman, F Burrows, LEN Neckers, N Rosen Annals of the New York Academy of Sciences 1113 (1), 202-216, 2007 | 660 | 2007 |
| Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1 B Panaretou, G Siligardi, P Meyer, A Maloney, JK Sullivan, S Singh, ... Molecular cell 10 (6), 1307-1318, 2002 | 656 | 2002 |
| The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations MO Leach, KM Brindle, JL Evelhoch, JR Griffiths, MR Horsman, A Jackson, ... British journal of cancer 92 (9), 1599-1610, 2005 | 618 | 2005 |
| Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies U Banerji, A O'Donnell, M Scurr, S Pacey, S Stapleton, Y Asad, ... Journal of Clinical Oncology 23 (18), 4152-4161, 2005 | 576 | 2005 |
| NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis SA Eccles, A Massey, FI Raynaud, SY Sharp, G Box, M Valenti, ... Cancer research 68 (8), 2850-2860, 2008 | 553 | 2008 |
| The Hsp90 molecular chaperone: an open and shut case for treatment LH Pearl, C Prodromou, P Workman Biochemical Journal 410 (3), 439-453, 2008 | 550 | 2008 |
| 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer PA Brough, W Aherne, X Barril, J Borgognoni, K Boxall, JE Cansfield, ... Journal of medicinal chemistry 51 (2), 196-218, 2008 | 520 | 2008 |
| New approaches to molecular cancer therapeutics I Collins, P Workman Nature chemical biology 2 (12), 689-700, 2006 | 499 | 2006 |
Johann de BonoInstitute of Cancer ResearchΗ διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα icr.ac.uk
